The company is currently working on regulatory submissions for the device in the US. Credit: Ultromics.

Ultromics has received breakthrough device status from the US Food and Drug Administration (FDA) for its artificial intelligence (AI)-enhanced platform to detect cardiac amyloidosis.

Referred to as EchoGo Amyloidosis, the platform leverages AI to analyse echocardiograms and detect cardiac amyloidosis from a single, commonly obtained ultrasound view of the heart.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Cardiac amyloidosis is a heterogeneous disease that arises from the accumulation of abnormal proteins in the heart tissue.

Ultromics CEO and founder Dr Ross Upton said: “This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease.

“We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients.”

Developed in conjunction with various clinical collaborators and supported by Janssen Biotech, EchoGo Amyloidosis forms an integral part of the company’s EchoGo Platform.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ultromics is currently working on regulatory submissions for the US, with the goal of obtaining approval for the device to push for commercialisation by early next year.

Janssen research and development strategy and operations global head and chief data science officer Dr Najat Khan said: “When applied to routine tests like echocardiograms, AI is demonstrating exciting potential to help facilitate earlier disease detection – with the goal of connecting patients with treatment sooner and ultimately driving better health outcomes.”

Last year, Ultromics received a breakthrough device designation for its HFpEF device, EchoGo Heart Failure, while marketing authorisation was received this year.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact